Ernexa Therapeutics Inc — Rendiconto Finanziario (NASDAQ:ERNA) | MetaTrader

Apri il grafico completo

Notizie

Ernexa pianifica trial per cancro ovarico con terapia cellulare ERNA-101

Ernexa Therapeutics riceve avviso di delisting dal Nasdaq per prezzo minimo

Proprietario del dieci percento di Ernexa Therapeutics, Cherington acquista azioni per 2 milioni di dollari

Ernexa therapeutics ten percent owner Cherington buys $2m in stock

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 2.47%

Programma commerciale giapponese seleziona Ernexa Therapeutics tra l’élite biotech

Japanese trade program selects Ernexa Therapeutics among elite biotech group

Why Penguin Solutions Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket - AAR (NYSE:AIR), Alpha Modus Holdings (NASDAQ:AMOD)

Ernexa receives FDA alignment for ovarian cancer cell therapy

Il titolo di Ernexa Therapeutics scende dopo la presentazione al meeting ASH

Ernexa Therapeutics stock falls after ASH meeting presentation

Ernexa reports promising preclinical data for cancer cell therapy